Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
NCT02387229 · Montreal Heart Institute · PHASE3 · terminated · last registry update 2025-06-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Consensus BRAIN-AF Executive Steering Committee to terminate.” | – | Registry record, Montreal Heart Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against F10 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-04Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + Apixaban (NCT07626411)
- 2026-05-19Results posted on the registry: Massachusetts General Hospital, Rivaroxaban + Warfarin (NCT03702582)
- 2026-05-05Also stopped (terminated): Ottawa Heart Institute Research Corporation, Rivaroxaban 15 MG Oral Tablet [Xarelto] (NCT03630055)
- 2026-04-24Results posted on the registry: Chiayi Christian Hospital, Rivaroxaban 10 MG (NCT05449327)
- 2026-04-20Results posted on the registry: AMAG Pharmaceuticals, Inc., Ciraparantag + Placebo (NCT04593784)
- 2026-04-20Also stopped (terminated): AMAG Pharmaceuticals, Inc., Ciraparantag + Placebo (NCT04593784)
- 2026-04-07Also stopped (withdrawn): University of Texas Southwestern Medical Center, Eloctate + Adynovate (NCT04690322)
- 2026-03-25Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + Apixaban (NCT07493304)
- 2026-03-13Phase 3 first posted: Columbia University, Warfarin + Apixaban (NCT07471139)
- 2026-03-12Phase 3 first posted: Population Health Research Institute, Rivaroxaban + ASA (NCT07468448)
- 2026-03-06Phase 3 first posted: Sunnybrook Health Sciences Centre, Edoxaban 15 mg + Aspirin or clopidogrel (NCT07454707)
- 2026-03-06Phase 3 first posted: Rawalpindi Institute of Cardiology, Rivoroxaban + Warfarin (NCT07456085)
- 2026-02-27Phase 3 first posted: Chulalongkorn University, Switching to low dose emicizumab (NCT07439055)
- 2026-02-25Phase 3 first posted: Meshalkin Research Institute of Pathology of Circulation, Apixaban + Warfarin (NCT07434661)
- 2026-02-23Also stopped (terminated): Anthos Therapeutics, Inc., Abelacimab + Apixaban (NCT05171049)
- 2026-02-20Results posted on the registry: Sheffield Teaching Hospitals NHS Foundation Trust, Aspirin 75mg + Aspirin 20mg (NCT04990791)
- 2026-02-18Phase 3 first posted: Hoffmann-La Roche, NXT007 + Emicizumab (NCT07416604)
- 2026-02-06Results posted on the registry: Lumosa Therapeutics Co., Ltd., LT3001 drug product + Placebo (NCT04809818)
- 2026-01-06Phase 3 first posted: Regeneron Pharmaceuticals, REGN7508 + REGN9933 (NCT07318610)
- 2025-12-10Also stopped (terminated): CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-14Phase 3 first posted: McMaster University, rivaroxaban and ASA + Low-molecular weight heparin (NCT07228663)
- 2025-11-10Results posted on the registry: CSL Behring, BE1116 + Placebo (NCT05568888)
- 2025-11-06Results posted on the registry: Pfizer, Standard of Care FIX Replacement therapy + Standard of Care FVIII Replacement therapy (NCT03587116)
- 2025-11-04Also stopped (withdrawn): Brian O'Neill MD, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa) (NCT04684212)
- 2025-10-02Phase 3 first posted: Rennes University Hospital, Anticoagulant treatment Rivaroxaban (NCT07202897)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision